GO:0106402 Lewis x epitope biosynthetic process: Glycan Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106402 describes the biosynthetic process that produces the Lewis x (LeX) epitope, a trisaccharide beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine, formed by alpha(1,3)-fucosylation of a type 2 histo-blood group antigen precursor disaccharide.
• The Lewis x epitope is widely expressed in normal tissues and is carried on O-mannose-linked glycans of phosphacan/RPTPbeta in the developing brain, as well as on glycolipids, glycoproteins, and proteoglycans.
• Fucosyltransferase 9 (FUT9) is a key enzyme that directs Lewis x modification, and its interaction with carrier proteins can be encoded by a molecular recognition code.
• In monocytes, Galectin-3 promotes sialyl Lewis X (sLeX) epitope biosynthesis, linking this pathway to inflammation and immune cell regulation.
• GlcNAc6ST-1 (CHST2) is implicated in generating 6-sulfo N-acetyllactosamine/Lewis x on CD44 in human monocytes and is induced by TNF-alpha.
• Altered Lewis x expression is associated with malignancy, particularly breast cancer and head and neck squamous cell carcinoma (HNSCC), making this pathway a target for cancer research.
Description
The Lewis x epitope biosynthetic process (GO:0106402) encompasses the chemical reactions and pathways that build the Lewis x trisaccharide, a carbohydrate structure expressed on glycolipids, glycoproteins, and proteoglycans throughout the nervous system and other tissues. This process is defined by the alpha(1,3)-fucosylation of the N-acetylglucosaminyl residue of a type 2 histo-blood group antigen precursor disaccharide, generating the characteristic beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine structure. The resulting epitope, often referred to as CD15 or SSEA-1, plays critical roles in cell adhesion, signaling, and development. Researchers study GO:0106402 because the Lewis x epitope is a key glycan determinant in neurobiology, immunology, and cancer biology. In the developing brain, Lewis x is predominantly carried on O-mannose-linked glycans of phosphacan/RPTPbeta, where it influences neural cell interactions. In the immune system, sialyl Lewis X (sLeX) biosynthesis is promoted by Galectin-3 in monocytes, highlighting a role in inflammation and immune surveillance. Moreover, GlcNAc6ST-1-mediated sulfation creates the 6-sulfo Lewis x epitope on CD44 in monocytes, a modification induced by TNF-alpha. Dysregulation of Lewis x biosynthesis is linked to malignancy, with high expression observed in breast cancer and head and neck squamous cell carcinoma. The pathway also intersects with pluripotency, as embryoglycan, a highly branched poly-N-acetyllactosamine carrying Lewis x, is present in pluripotent stem cells and early embryonic cells. Understanding the enzymes, substrates, and regulatory mechanisms of GO:0106402 is therefore essential for both basic glycobiology and translational research.
Lewis x epitope biosynthetic process At A Glance
| GO ID | GO:0106402 |
|---|---|
| GO term | Lewis x epitope biosynthetic process |
| Ontology | biological_process |
| Synonym | sialyl-Lewis X biosynthetic process; sLeX biosynthetic process |
| Major function | Synthesis of the Lewis x trisaccharide epitope on glycoconjugates |
| Key enzymes | Fucosyltransferases (e.g., FUT9), sulfotransferases (e.g., CHST2/GlcNAc6ST-1) |
| Substrate | Type 2 histo-blood group antigen precursor disaccharide |
| Product | Lewis x epitope (CD15/SSEA-1) on glycolipids, glycoproteins, proteoglycans |
| Tissue context | Nervous system, monocytes, pluripotent stem cells, embryonic cells |
What Is GO:0106402?
GO:0106402, Lewis x epitope biosynthetic process, is the biological process comprising the chemical reactions and pathways that result in the formation of a Lewis x epitope. This epitope is a trisaccharide with the structure beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine, expressed on several glycolipids, glycoproteins, and proteoglycans of the nervous system. The related Lewis x epitope is formed by alpha(1,3) fucosylation of the N-acetylglucosaminyl residue of a type 2 histo-blood group antigen precursor disaccharide.
Why Is Lewis x epitope biosynthetic process Important in Cell Biology?
The Lewis x epitope biosynthetic process is fundamentally important because the Lewis x glycan serves as a critical recognition determinant in cell-cell interactions, development, and immunity. In the nervous system, Lewis x carried on O-mannose-linked glycans of phosphacan/RPTPbeta modulates neural development and signaling. In the immune system, sialyl Lewis X biosynthesis in monocytes is promoted by Galectin-3, implicating this pathway in inflammatory responses. The epitope is also a marker of pluripotent stem cells through embryoglycan structures. Clinically, altered Lewis x expression is associated with cancer progression, particularly breast cancer and HNSCC, making the biosynthetic enzymes attractive targets for diagnosis and therapy. Furthermore, the interaction between FUT9 and carrier proteins reveals a molecular code for Lewis X modification, offering insights into specificity of glycosylation.
• Lewis x is highly expressed in normal tissues, serving as a developmental and differentiation marker.
• The pathway is essential for nervous system development via O-mannose-linked glycans on phosphacan/RPTPbeta.
• Galectin-3 promotes sialyl Lewis X biosynthesis in monocytes, linking the pathway to inflammation.
• GlcNAc6ST-1 generates 6-sulfo Lewis x on CD44 in monocytes and is induced by TNF-alpha.
• Embryoglycan, a poly-N-acetyllactosamine carrying Lewis x, is present in pluripotent stem cells and early embryos.
• Altered Lewis x expression is associated with breast cancer and head and neck squamous cell carcinoma.
• FUT9 interaction with carrier proteins provides a molecular code for Lewis X modification.
• Multivalent Lewis X-MGL-1 interactions are biologically relevant and can be evaluated for functional studies.
• The pathway is a potential target for anti-inflammatory and anti-cancer therapies.
• Understanding the biosynthetic process aids in designing glycan-based diagnostics and therapeutics.
What Happens During Lewis x epitope biosynthetic process?
Formation of the Type 2 Precursor Disaccharide
In simple terms: First, a basic sugar chain is built on a protein or lipid carrier.
The biosynthetic process begins with the assembly of a type 2 histo-blood group antigen precursor disaccharide, which consists of N-acetyllactosamine (Galbeta1-4GlcNAc) attached to a growing glycan chain on a glycoprotein, glycolipid, or proteoglycan. This precursor is the substrate for subsequent fucosylation. In the developing brain, this precursor is presented on O-mannose-linked glycans of phosphacan/RPTPbeta, providing a scaffold for Lewis x expression.
Alpha(1,3)-Fucosylation by Fucosyltransferases
In simple terms: An enzyme adds a fucose sugar to the chain, creating the Lewis x tag.
The key step in GO:0106402 is the alpha(1,3)-fucosylation of the N-acetylglucosaminyl residue of the type 2 precursor disaccharide. This reaction is catalyzed by fucosyltransferases, notably fucosyltransferase 9 (FUT9), which directs Lewis x modification through interaction with specific carrier proteins. The resulting trisaccharide, beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine, constitutes the Lewis x epitope.
Sialylation and Sulfation Modifications
In simple terms: The Lewis x structure can be further modified with sialic acid or sulfate groups.
The Lewis x epitope can be further modified to generate sialyl Lewis X (sLeX) or 6-sulfo Lewis x. In monocytes, Galectin-3 promotes sialyl Lewis X epitope biosynthesis, enhancing the diversity of Lewis x-containing glycans. Additionally, GlcNAc6ST-1 (CHST2) is implicated in the generation of 6-sulfo N-acetyllactosamine/Lewis x on CD44, a modification induced by TNF-alpha. These modifications expand the functional repertoire of the Lewis x epitope.
Presentation on Glycoconjugates
In simple terms: The finished Lewis x sugar is displayed on proteins or lipids on the cell surface.
Once synthesized, the Lewis x epitope is expressed on several glycolipids, glycoproteins, and proteoglycans of the nervous system. In pluripotent stem cells and early embryonic cells, Lewis x is carried on embryoglycan, a highly branched poly-N-acetyllactosamine. The presentation of Lewis x on carrier molecules such as CD44 and phosphacan/RPTPbeta determines its biological functions in cell adhesion, signaling, and development.
Recognition and Functional Interactions
In simple terms: Other proteins recognize the Lewis x sugar and trigger biological effects.
The Lewis x epitope serves as a recognition determinant for lectins such as Galectin-3 and MGL-1. Multivalent Lewis X-MGL-1 interactions have been biologically evaluated, demonstrating the importance of glycan valency in binding. Galectin-3 promotes sialyl Lewis X biosynthesis in monocytes, creating a feedback loop that amplifies Lewis x expression. These interactions mediate cell-cell adhesion, immune cell trafficking, and developmental signaling.
Key Genes Involved in GO:0106402 Lewis x epitope biosynthetic process
The following genes and proteins are experimentally implicated in the biosynthesis, modification, and functional presentation of the Lewis x epitope.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FUT9 | Alpha(1,3)-fucosyltransferase that directs Lewis x modification | Key enzyme for Lewis x synthesis; interaction with carrier proteins defines a molecular code |
| CHST2 (GlcNAc6ST-1) | Generates 6-sulfo N-acetyllactosamine/Lewis x on CD44 | Induced by TNF-alpha in monocytes; links sulfation to Lewis x biology |
| LGALS3 (Galectin-3) | Promotes sialyl Lewis X epitope biosynthesis in monocytes | Connects Lewis x pathway to inflammation and immune regulation |
| PTPRZ1 (phosphacan/RPTPbeta) | Carries O-mannose-linked Lewis x glycans in developing brain | Major glycan carrier underlying Lewis x expression in neural development |
| CD44 | Cell surface glycoprotein carrying 6-sulfo Lewis x | Model for studying Lewis x modification on specific protein carriers |
| FUT4 | Alpha(1,3)-fucosyltransferase potentially involved in Lewis x synthesis | Candidate enzyme for Lewis x biosynthesis in various tissues |
| FUT5 | Fucosyltransferase potentially contributing to Lewis x synthesis | May compensate for other fucosyltransferases in Lewis x production |
| FUT6 | Fucosyltransferase potentially contributing to Lewis x synthesis | Relevant for sialyl Lewis X biosynthesis in cancer |
| FUT7 | Fucosyltransferase potentially contributing to sialyl Lewis X synthesis | Linked to selectin ligand formation in immune cells |
| B3GNT2 | Beta-1,3-N-acetylglucosaminyltransferase for poly-N-acetyllactosamine | Builds the precursor backbone for Lewis x epitopes |
| B4GALT1 | Beta-1,4-galactosyltransferase for type 2 chain synthesis | Creates the N-acetyllactosamine precursor for fucosylation |
| MGAT1 | N-acetylglucosaminyltransferase for complex N-glycans | May influence Lewis x presentation on N-glycans |
| ST3GAL3 | Sialyltransferase for sialyl Lewis X synthesis | Modifies Lewis x to sLeX, affecting selectin binding |
| ST3GAL4 | Sialyltransferase for sialyl Lewis X synthesis | Contributes to sLeX biosynthesis in monocytes |
| MGL-1 (CLEC10A) | Lectins that recognize Lewis x | Mediates biological interactions with Lewis x epitopes |
| SDC1 (Syndecan-1) | Proteoglycan carrier of Lewis x | Potential carrier for Lewis x in nervous system and cancer |
| NCAM1 | Neural cell adhesion molecule carrying Lewis x | Relevant for Lewis x function in nervous system |
| GPC1 (Glypican-1) | Proteoglycan carrier of Lewis x | May present Lewis x on cell surfaces |
How Is Lewis x epitope biosynthetic process Regulated?
The Lewis x epitope biosynthetic process is regulated at multiple levels. In human monocytes, GlcNAc6ST-1 (CHST2) is induced by TNF-alpha, leading to increased generation of 6-sulfo N-acetyllactosamine/Lewis x on CD44. Galectin-3 promotes sialyl Lewis X epitope biosynthesis in monocytes, suggesting a regulatory role for galectins in this pathway. The interaction between FUT9 and carrier proteins provides a molecular code that determines the specificity of Lewis X modification, indicating that protein-protein interactions regulate where and when Lewis x is synthesized. Additionally, the presence of embryoglycan in pluripotent stem cells and early embryonic cells suggests developmental regulation of Lewis x biosynthesis.
Lewis x epitope biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FUT9 | Cancer (breast, HNSCC); altered Lewis x expression | FUT9 knockout or overexpression in cancer cell lines |
| LGALS3 | Inflammation; monocyte sialyl Lewis X biosynthesis | LGALS3 knockout in monocytes/macrophages |
| CHST2 | Inflammatory response; 6-sulfo Lewis x on CD44 | CHST2 knockout or knockdown in monocytes treated with TNF-alpha |
| PTPRZ1 | Neurodevelopment; O-mannose-linked Lewis x | PTPRZ1 knockout in neural cell models |
| CD44 | Cancer progression; 6-sulfo Lewis x carrier | CD44 knockout or point mutation in cancer cells |
Lewis x in Cancer
Altered expression of the Lewis x epitope is associated with malignancy, particularly breast cancer and head and neck squamous cell carcinoma (HNSCC). Lewis x and related structures such as sialyl Lewis X are implicated in tumor progression, metastasis, and poor prognosis. The biosynthetic enzymes, including fucosyltransferases and sulfotransferases, are potential targets for cancer diagnostics and therapeutics. High Lewis x expression in normal tissues also provides a baseline for understanding cancer-associated changes.
Lewis x in Inflammation and Immune Regulation
In monocytes, Galectin-3 promotes sialyl Lewis X epitope biosynthesis, linking the Lewis x pathway to inflammatory responses. GlcNAc6ST-1 is induced by TNF-alpha and generates 6-sulfo Lewis x on CD44, a modification that may influence immune cell trafficking and adhesion. These findings suggest that dysregulation of Lewis x biosynthesis contributes to inflammatory diseases and immune disorders.
Lewis x in Neurodevelopment and Neurological Disorders
The Lewis x epitope is highly expressed in the developing brain, predominantly on O-mannose-linked glycans of phosphacan/RPTPbeta. This specific presentation suggests roles in neural cell adhesion, migration, and synaptic organization. Disruption of Lewis x biosynthesis could therefore impact neurodevelopment and may be relevant to neurological conditions, although direct disease associations require further investigation.
From Lewis x epitope biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FUT9 knockout abolish Lewis x biosynthesis? | FUT9 knockout cell line (e.g., HEK293 or cancer cells) |
| How does Galectin-3 regulate sialyl Lewis X biosynthesis? | LGALS3 overexpression or knockout in monocytes |
| What is the role of 6-sulfo Lewis x on CD44? | CHST2 knockout or CD44 point mutation in monocytes |
| How is Lewis x presented on phosphacan/RPTPbeta? | PTPRZ1 knockout or tagged knock-in in neural cells |
| Can Lewis x biosynthesis be redirected by altering fucosyltransferase specificity? | FUT9 point mutation or knock-in of alternative fucosyltransferases |
| Does Lewis x expression affect pluripotency? | Overexpression or knockout of glycosyltransferases in pluripotent stem cells |
How to Study the Lewis x epitope biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry glycomics | Structural identification of Lewis x and modified glycans | Confirming biosynthetic products and modifications |
| Lectin/antibody staining | Presence and localization of Lewis x epitopes | Tissue and cell expression profiling |
| Fucosyltransferase activity assay | Enzymatic activity of FUT9 and related enzymes | Functional characterization of wild-type and mutant enzymes |
| CRISPR knockout screening | Genes required for Lewis x biosynthesis | Discovery of novel pathway regulators |
| Flow cytometry | Cell surface Lewis x levels | Quantifying expression changes in immune cells |
| Immunohistochemistry | Tissue distribution of Lewis x | Comparative expression studies in normal and cancer tissues |
| Glycoproteomics | Carrier proteins modified with Lewis x | Identifying specific glycoprotein carriers |
| Binding assays (e.g., MGL-1) | Lectin-Lewis x interaction affinity | Evaluating functional recognition |
Glycan Analysis by Mass Spectrometry
Mass spectrometry-based glycomics and glycoproteomics are essential for characterizing Lewis x structures. These methods can identify the trisaccharide beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine on glycoproteins and glycolipids, and detect modifications such as sialylation and sulfation. Researchers use these techniques to confirm the products of GO:0106402 and to quantify changes in Lewis x expression across conditions.
Lectins and Antibodies for Detection
Lewis x epitopes are commonly detected using specific antibodies (e.g., anti-CD15/SSEA-1) and lectins such as MGL-1. Multivalent Lewis X-MGL-1 interactions can be evaluated using binding assays to study avidity and specificity. Immunohistochemistry and flow cytometry with these reagents allow researchers to localize and quantify Lewis x expression in tissues and cells.
Enzymatic Assays for Fucosyltransferases
Fucosyltransferase activity assays using fluorescent or radiolabeled substrates measure the enzymatic step of Lewis x biosynthesis. These assays can determine the kinetic properties of FUT9 and other fucosyltransferases, and assess how mutations affect catalytic activity. Such methods are critical for linking genotype to biochemical function in GO:0106402.
CRISPR-Based Genetic Screens
CRISPR knockout libraries targeting glycosyltransferase genes can identify novel regulators of Lewis x biosynthesis. By selecting for loss or gain of Lewis x expression using lectin or antibody staining, researchers can uncover genes required for GO:0106402. These screens are powerful for discovering unanticipated components of the pathway.
How CRISPR Can Be Used to Study GO:0106402 Lewis x epitope biosynthetic process
Knockout
CRISPR knockout of genes such as FUT9, CHST2, or LGALS3 can abolish or reduce Lewis x biosynthesis, allowing researchers to test the requirement of each enzyme in GO:0106402. For example, FUT9 knockout cells show loss of Lewis x modification, confirming its role as a key fucosyltransferase. Knockout of CHST2 prevents 6-sulfo Lewis x formation on CD44.
Point Mutation
CRISPR point mutation can be used to introduce catalytic-dead mutations in fucosyltransferases or sulfotransferases, dissecting the enzymatic steps of Lewis x biosynthesis without completely removing the protein. This approach is valuable for studying the molecular code of FUT9 interaction with carrier proteins.
Knock-in
Knock-in of tagged versions of enzymes or carrier proteins (e.g., FLAG-tagged FUT9 or CD44) enables tracking of Lewis x biosynthesis in live cells and tissues. Tagged knock-in models can reveal the subcellular localization and trafficking of glycosyltransferases involved in GO:0106402.
Overexpression
CRISPR activation or cDNA overexpression of FUT9, LGALS3, or CHST2 can enhance Lewis x biosynthesis, providing gain-of-function models to study downstream effects. Overexpression of Galectin-3 promotes sialyl Lewis X biosynthesis in monocytes, demonstrating the utility of this approach.
How EDITGENE Supports Lewis x epitope biosynthetic process Research
Researchers studying Lewis x epitope biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in glycan synthesis, how specific mutations affect enzyme function, and where the epitope is presented on carrier proteins. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for Lewis x epitope biosynthetic process research.
Frequently Asked Questions About Lewis x epitope biosynthetic process
What is GO:0106402?
GO:0106402 is the Gene Ontology term for Lewis x epitope biosynthetic process, the chemical reactions and pathways that form the Lewis x trisaccharide, beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine, on glycoconjugates.
What genes are involved in Lewis x epitope biosynthetic process?
Key genes include FUT9, which encodes the alpha(1,3)-fucosyltransferase that directs Lewis x modification, CHST2 (GlcNAc6ST-1) for 6-sulfo Lewis x, LGALS3 (Galectin-3) for sialyl Lewis X biosynthesis, and PTPRZ1 (phosphacan/RPTPbeta) as a major carrier in the brain.
What is the Lewis x epitope?
The Lewis x epitope is a trisaccharide with the structure beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine, expressed on glycolipids, glycoproteins, and proteoglycans, and is also known as CD15 or SSEA-1.
How is Lewis x synthesized?
Lewis x is synthesized by alpha(1,3)-fucosylation of the N-acetylglucosaminyl residue of a type 2 histo-blood group antigen precursor disaccharide, catalyzed by fucosyltransferases such as FUT9.
What is sialyl Lewis X?
Sialyl Lewis X (sLeX) is a sialylated form of the Lewis x epitope. Galectin-3 promotes sialyl Lewis X epitope biosynthesis in monocytes, linking it to inflammation.
What diseases are associated with Lewis x?
Altered Lewis x expression is associated with malignancy, particularly breast cancer and head and neck squamous cell carcinoma (HNSCC). It is also implicated in inflammatory responses through Galectin-3 and CHST2.
How can I study Lewis x biosynthesis in the lab?
Common methods include mass spectrometry glycomics, lectin/antibody staining, fucosyltransferase activity assays, and CRISPR knockout screening.
What is the role of FUT9 in Lewis x biosynthesis?
FUT9 is a fucosyltransferase that directs Lewis X modification through interaction with carrier proteins, providing a molecular code for where Lewis x is added.
Is Lewis x expressed in the brain?
Yes, Lewis x is expressed in the developing brain, predominantly on O-mannose-linked glycans of phosphacan/RPTPbeta.
What CRISPR models are available for Lewis x research?
EDITGENE offers knockout, point mutation, knock-in, tagged knock-in, and overexpression models for genes such as FUT9, CHST2, LGALS3, and PTPRZ1, as well as CRISPR library screening.
Conclusion
The Lewis x epitope biosynthetic process (GO:0106402) is a central pathway in glycobiology, producing a trisaccharide that functions in nervous system development, immune regulation, and pluripotency. Key enzymes such as FUT9 and CHST2, along with regulatory proteins like Galectin-3, control the synthesis and modification of Lewis x on specific carrier molecules. Dysregulation of this pathway is linked to cancer and inflammatory conditions, making it a compelling target for further research. By leveraging CRISPR-based models and advanced glycomics, researchers can dissect the molecular mechanisms of Lewis x biosynthesis and translate these findings into clinical applications. EDITGENE provides the tools and expertise to accelerate discoveries in this field.
References
- 1. Judge J et al.. 2025. Galectin-3 promotes sialyl Lewis X epitope biosynthesis in monocytes.. J Leukoc Biol 117(12) PMID: 41315014
- 2. Yaji S et al.. 2015. Major glycan structure underlying expression of the Lewis X epitope in the developing brain is O-mannose-linked glycans on phosphacan/RPTPβ.. Glycobiology 25(4):376-85 PMID: 25361541
- 3. Tjew SL et al.. 2005. Expression of N-acetylglucosamine 6-O-sulfotransferases (GlcNAc6STs)-1 and -4 in human monocytes: GlcNAc6ST-1 is implicated in the generation of the 6-sulfo N-acetyllactosamine/Lewis x epitope on CD44 and is induced by TNF-alpha.. Glycobiology 15(7):7C-13C PMID: 15728736
- 4. Muramatsu T. 2017. Embryoglycan: a highly branched poly-N-acetyllactosamine in pluripotent stem cells and early embryonic cells.. Glycoconj J 34(6):701-712 PMID: 27188587
- 5. Eriksson M et al.. 2014. Biological evaluation of multivalent lewis X-MGL-1 interactions.. Chembiochem 15(6):844-51 PMID: 24616167
- 6. Croce MV. 2022. An Introduction to the Relationship Between Lewis x and Malignancy Mainly Related to Breast Cancer and Head Neck Squamous Cell Carcinoma (HNSCC).. Cancer Invest 40(2):173-183 PMID: 34908476
- 7. Croce MV et al.. 2007. Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision.. Pathol Oncol Res 13(2):130-8 PMID: 17607374
- 8. Saito T et al.. 2022. An embeddable molecular code for Lewis X modification through interaction with fucosyltransferase 9.. Commun Biol 5(1):676 PMID: 35831428
